Provide Immunologic Rationale for IL-23 Directed Therapy in IBD

In this informative FAQ video module, Sarah Enslin, a physician assistant at the University of Rochester Medical Center, discusses the role of Interleukin-23 (IL-23) in treating immune-mediated inflammatory diseases, particularly inflammatory bowel disease (IBD). Sponsored by Johnson & Johnson, this video highlights how IL-23 directed therapies have revolutionized the management of IBD, including Crohn’s disease and ulcerative colitis.

Sarah explains how IL-23, primarily produced by dendritic cells and macrophages, is central to the development of TH17 cells, a subset of CD4+ T cells involved in chronic inflammation. In IBD, IL-23 signaling promotes the activation and differentiation of TH17 cells in the intestinal mucosa, which secrete pro-inflammatory cytokines like IL-17, damaging the intestinal barrier, leading to inflammation and disease progression.

One of the leading therapies in this class is Guselkumab, a monoclonal antibody that selectively targets the p19 subunit of IL-23, inhibiting its signaling pathway. By targeting IL-23 without affecting other immune responses (such as IL-12 driven pathways), Guselkumab can reduce TH17 cell activation and the inflammation they cause, leading to improved disease outcomes. This selective blockade not only benefits the gut but also extends to skin and joints, offering a comprehensive approach to treating IBD.

Clinical trials have demonstrated the efficacy of IL-23 directed therapies, with patients experiencing significant reductions in disease severity, improved clinical symptoms, and an overall enhanced quality of life.

This module is a valuable resource for advanced practice providers, including physician assistants and nurse practitioners, who are looking to expand their knowledge on the latest IBD treatment advancements and IL-23 inhibition therapies. For more information visit the GHAPP website or download the GHAPP ACE app.